NO20074025L - Konjugater for dobbel billeddannelse og radiokjemoterapi:sammensetninger, fremstilling og anvendelse - Google Patents

Konjugater for dobbel billeddannelse og radiokjemoterapi:sammensetninger, fremstilling og anvendelse

Info

Publication number
NO20074025L
NO20074025L NO20074025A NO20074025A NO20074025L NO 20074025 L NO20074025 L NO 20074025L NO 20074025 A NO20074025 A NO 20074025A NO 20074025 A NO20074025 A NO 20074025A NO 20074025 L NO20074025 L NO 20074025L
Authority
NO
Norway
Prior art keywords
dual imaging
radiochemistry
conjugates
compositions
preparation
Prior art date
Application number
NO20074025A
Other languages
English (en)
Norwegian (no)
Inventor
E Edmund Kim
David J Yang
Dongfang Yu
Mithu Chanda
Ali Azhdarinia
Changsok Oh
Original Assignee
Univ Texas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas filed Critical Univ Texas
Publication of NO20074025L publication Critical patent/NO20074025L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00Cosmetics or similar toiletry preparations
    • A61K8/18Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/58Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing atoms other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur or phosphorus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549Sugars, nucleosides, nucleotides or nucleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0002General or multifunctional contrast agents, e.g. chelated agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/04X-ray contrast preparations
    • A61K49/0433X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0438Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0491Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08BPOLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0024Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid beta-D-Glucans; (beta-1,3)-D-Glucans, e.g. paramylon, coriolan, sclerotan, pachyman, callose, scleroglucan, schizophyllan, laminaran, lentinan or curdlan; (beta-1,6)-D-Glucans, e.g. pustulan; (beta-1,4)-D-Glucans; (beta-1,3)(beta-1,4)-D-Glucans, e.g. lichenan; Derivatives thereof
    • C08B37/00272-Acetamido-2-deoxy-beta-glucans; Derivatives thereof
    • C08B37/003Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Birds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Saccharide Compounds (AREA)
  • Apparatus For Radiation Diagnosis (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20074025A 2005-01-05 2007-08-03 Konjugater for dobbel billeddannelse og radiokjemoterapi:sammensetninger, fremstilling og anvendelse NO20074025L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64155905P 2005-01-05 2005-01-05
PCT/US2006/000269 WO2006074272A2 (en) 2005-01-05 2006-01-05 Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications

Publications (1)

Publication Number Publication Date
NO20074025L true NO20074025L (no) 2007-09-27

Family

ID=36648161

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20074025A NO20074025L (no) 2005-01-05 2007-08-03 Konjugater for dobbel billeddannelse og radiokjemoterapi:sammensetninger, fremstilling og anvendelse

Country Status (11)

Country Link
US (2) US8147805B2 (pt)
EP (1) EP1846042A2 (pt)
JP (1) JP2008531755A (pt)
KR (1) KR101313712B1 (pt)
CN (1) CN101137398B (pt)
AU (2) AU2006204045B2 (pt)
BR (1) BRPI0606395A2 (pt)
CA (1) CA2593256A1 (pt)
IL (1) IL184415A0 (pt)
NO (1) NO20074025L (pt)
WO (1) WO2006074272A2 (pt)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7067111B1 (en) * 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
PL367102A1 (en) 2001-05-02 2005-02-21 Purdue Research Foundation Treatment and diagnosis of macrophage mediated disease
US8043603B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
US8043602B2 (en) 2002-02-07 2011-10-25 Endocyte, Inc. Folate targeted enhanced tumor and folate receptor positive tissue optical imaging technology
EP1629281B1 (en) 2003-05-30 2008-10-29 Purdue Research Foundation Diagnostic method for atherosclerosis
US9050378B2 (en) * 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
ITMI20040928A1 (it) 2004-05-07 2004-08-07 Uni Di Bologna Dipartiment O D Procedura per la preparazione di coniugati della doxorubicina con l'albumina umana lattosaminata
WO2006071754A2 (en) * 2004-12-23 2006-07-06 Purdue Research Foundation Positron emission tomography imaging method
US8703097B2 (en) * 2005-02-11 2014-04-22 University Health Network Compositions and method for multimodal imaging
US9820986B2 (en) * 2005-03-04 2017-11-21 Taiwan Hopaz Chems, Mfg. Co., Ltd. Glycopeptide compositions
JP5175723B2 (ja) 2005-07-05 2013-04-03 パーデュー・リサーチ・ファウンデーション 単球介在性疾患を治療するための組成物の調製
ITMI20051743A1 (it) * 2005-09-20 2007-03-21 Uni Di Bologna Dipartimento Di Patologia Spa Uso di coniugati della doxorubicina con albumina lattosaminata
EP1940473A2 (en) * 2005-09-23 2008-07-09 Purdue Research Foundation Multiphoton in vivo flow cytometry method and device
WO2007126730A1 (en) * 2006-03-29 2007-11-08 Isotherapeautics Group Llc Radionuclide therapy for urinary bladder cancer
WO2007120153A1 (en) * 2006-04-19 2007-10-25 The Board Of Regents Of The University Of Texas System Compositions and methods for cellular imaging and therapy
US10925977B2 (en) 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
US8685752B2 (en) 2006-11-03 2014-04-01 Purdue Research Foundation Ex vivo flow cytometry method and device
US20100104511A1 (en) * 2006-11-22 2010-04-29 The Board Of Regents Of The University Of Texas System Methods and compositions using chelator-antibody conjugates
US8586595B2 (en) * 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
MX340566B (es) * 2007-03-27 2016-07-14 Radiomedix Inc Composiciones para formacion de imagen objetivo y terapia.
US8961926B2 (en) * 2007-05-25 2015-02-24 Purdue Research Foundation Method of imaging localized infections
US20120277409A1 (en) * 2007-06-04 2012-11-01 Board Of Regents, The University Of Texas System Metal-polysaccharide conjugates: compositions, synthesis and methods for cancer therapy
GB0725070D0 (en) * 2007-12-21 2008-01-30 Iopharma Technologies Ab Product
DE102008045937B4 (de) * 2008-04-11 2017-01-26 Johannes-Gutenberg-Universität Mainz Radiopharmakon aus einem Metallion und einem Markierungsvorläufer und Verwendung des Radiopharmakons
US20090264753A1 (en) * 2008-04-22 2009-10-22 General Electric Company Method & system for multi-modality imaging of sequentially obtained pseudo-steady state data
WO2009137428A2 (en) * 2008-05-05 2009-11-12 Emory University Methods of determining renal function using technetium-99m tricarbonyl-nitrilotriacetic acid
EP2300840B1 (en) * 2008-07-09 2020-09-23 Koninklijke Philips N.V. Physiological pharmacokinetic analysis for combined molecular mri and dynamic pet imaging
AU2010234459A1 (en) * 2009-04-08 2011-11-03 The Regents Of The University Of California Human protein scaffold with controlled serum pharmacokinetics
JP2011063572A (ja) * 2009-09-18 2011-03-31 Kyushu Univ 診断用造影剤
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
WO2011090710A2 (en) 2009-12-28 2011-07-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Composite probes and use thereof in super resolution methods
WO2011155805A2 (ko) * 2010-06-11 2011-12-15 국립암센터 종양 및 감시림프절에 특이적인 방사성동위원소 표지된 엽산 결합 인혈청 알부민
CN102218150B (zh) * 2010-08-17 2013-01-30 扬州大学 肝靶向纳米Fe3O4MRI造影剂及制备方法
CN102398026B (zh) * 2010-09-10 2013-10-23 聚和国际股份有限公司 甲壳素修饰的纳米金粒子及其制造方法
CN102558291B (zh) * 2010-12-17 2014-03-12 北京大学人民医院 一种双模分子影像探针
JP2014522808A (ja) * 2011-06-17 2014-09-08 サントル ナショナル ドゥ ラ ルシェルシュ シアンティフィク 二官能性ホスホネートキレート剤
PL2721045T3 (pl) 2011-06-20 2017-11-30 Radiomedix Inc. Kompozycie, metody syntezy i zastosowanie węglowodanowych środków ukierunkowanych
US10314594B2 (en) 2012-12-14 2019-06-11 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
US10813630B2 (en) 2011-08-09 2020-10-27 Corquest Medical, Inc. Closure system for atrial wall
US10307167B2 (en) 2012-12-14 2019-06-04 Corquest Medical, Inc. Assembly and method for left atrial appendage occlusion
EP2788087A4 (en) * 2011-12-06 2015-08-26 Ohio State Innovation Foundation Non-ionic, low-osmolar contrast agents for the administration of antisense oligonucleotides and the treatment of diseases
EP2830666B1 (en) * 2012-03-26 2020-01-08 Board of Regents, The University of Texas System Efficient synthesis of ethylenedicysteine-sugar conjugates for imaging and therapy
US9675715B2 (en) 2012-07-20 2017-06-13 Canon Kabushiki Kaisha Contrast agent for photoacoustic imaging
US20140142689A1 (en) 2012-11-21 2014-05-22 Didier De Canniere Device and method of treating heart valve malfunction
WO2014090648A1 (en) * 2012-12-12 2014-06-19 Solvay Specialty Polymers Italy S.P.A. Fluorinated chitosan derivatives
US10035009B2 (en) 2013-04-15 2018-07-31 The Board Of Trustees Of The Leland Stanford Junior University Systems and methods for treating pancreatic cancer
US9566443B2 (en) 2013-11-26 2017-02-14 Corquest Medical, Inc. System for treating heart valve malfunction including mitral regurgitation
WO2015200187A1 (en) 2014-06-27 2015-12-30 Reiley Pharmaceuticals, Inc. Conjugates derived from non-steroidal anti-inflammatory drugs and methods of use thereof in imaging
BE1021191B1 (fr) * 2014-08-29 2015-10-27 Anmi S.A. Kit pour radiomarquage.
US11027030B2 (en) 2014-08-29 2021-06-08 Anmi S.A. Kit for radiolabelling
US10842626B2 (en) 2014-12-09 2020-11-24 Didier De Canniere Intracardiac device to correct mitral regurgitation
EP3242688B1 (en) 2015-01-09 2020-01-29 Reiley Pharmaceuticals, Inc. Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers
WO2017090047A1 (en) 2015-11-27 2017-06-01 Technology Innovation Momentum Fund (Israel) Limited Partnership Glucosamine and derivatives thereof in imaging
CN108761078A (zh) * 2018-05-19 2018-11-06 复旦大学 胰腺癌基底微绒毛的检测方法和应用
IL271681A (en) 2018-07-18 2020-01-30 Vyripharm Entpr Llc Systems and methods for integrated and comprehensive management of cannabis products
KR20200047322A (ko) 2018-10-26 2020-05-07 전남대학교병원 체내위치확인 시스템
CN114555131A (zh) * 2019-08-19 2022-05-27 纳维迪亚生物制药有限公司 用于消融m2巨噬细胞和髓源性抑制细胞的组合物和相关方法
CN110563859B (zh) * 2019-09-19 2021-07-23 湖北医药学院 抗肝癌药物亚硒酸酯化壳聚糖铜的一锅合成法及应用
CN110981940A (zh) * 2019-11-08 2020-04-10 复旦大学附属肿瘤医院 一种pd-l1结合剂、金属配合物及其使用方法和用途
DE102019135564B4 (de) * 2019-12-20 2022-05-19 Johannes-Gutenberg-Universität Mainz Verbindung für Smart-Drug-Delivery und pharmazeutisches Kit für duale nuklearmedizinisch-cytotoxische Theranostik
AU2021416061B2 (en) * 2020-12-28 2024-06-06 Boston Scientific Scimed, Inc. Polysaccharides having improved radiocontrast properties
US20220305146A1 (en) * 2021-03-26 2022-09-29 Vyripharm Enterprises, Inc. Radiopharmaceutical compositions and methods for infectious disease diagnosis and therapy
WO2023201377A2 (en) * 2022-04-15 2023-10-19 The General Hospital Corporation Scission-enhanced nuclear imaging and treatment
CN116655928B (zh) * 2023-04-18 2025-08-29 扬州大学 一种基于半胱氨酸的超分子手性光热剂及其应用

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE465907B (sv) * 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US4861869A (en) 1986-05-29 1989-08-29 Mallinckrodt, Inc. Coupling agents for joining radionuclide metal ions with biologically useful proteins
US5707604A (en) * 1986-11-18 1998-01-13 Access Pharmaceuticals, Inc. Vivo agents comprising metal-ion chelates with acidic saccharides and glycosaminoglycans, giving improved site-selective localization, uptake mechanism, sensitivity and kinetic-spatial profiles
AU601536B2 (en) 1986-12-30 1990-09-13 Nihon Medi-Physics Co., Ltd. High molecular compound comprising unit of asialoglycoprotein acceptor-directing compound and unit of chelate-forming compound chemically bonded thereto, and its utilization
US4965392A (en) 1987-03-26 1990-10-23 Neorx Corporation Chelating compounds for metal-radionuclide labeled proteins
US5364613A (en) * 1989-04-07 1994-11-15 Sieving Paul F Polychelants containing macrocyclic chelant moieties
US5116599A (en) 1989-07-31 1992-05-26 Johns Hopkins Univ. Perfluoro-t-butyl-containing compounds for use in fluorine-19 nmr and/or mri
CA2080685A1 (en) 1990-04-17 1991-10-18 Alfons Verbruggen Method and kit for preparing technetium-99m complexes
WO1991018908A1 (de) * 1990-06-01 1991-12-12 Institut für Diagnostikforschung GmbH an der Freien Universität Berlin CYCLOPENTADIENYLCARBONYL-99mTc-KOMPLEXE, VERFAHREN ZU IHRER HERSTELLUNG SOWIE IHRE VERWENDUNG IN DER DIAGNOSTIK
ATE152455T1 (de) * 1990-08-17 1997-05-15 Drug Delivery System Inst Ltd N-acetylcarboxymethylchitosanderivat und verfahren zur herstellung
JP2894879B2 (ja) * 1991-10-04 1999-05-24 日本メジフィジックス株式会社 診断用造影剤
WO1994005203A1 (en) * 1992-09-04 1994-03-17 The General Hospital Corporation Biocompatible polymers containing diagnostic or therapeutic moieties
US5605672A (en) 1993-06-09 1997-02-25 The General Hospital Corporation Blood pool imaging composition and method of its use
US5840332A (en) * 1996-01-18 1998-11-24 Perio Products Ltd. Gastrointestinal drug delivery system
US5986074A (en) 1996-05-06 1999-11-16 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5955053A (en) 1996-05-06 1999-09-21 Emory University Metal chelates as pharmaceutical imaging agents, processes of making such and uses thereof
US5900228A (en) 1996-07-31 1999-05-04 California Institute Of Technology Bifunctional detection agents having a polymer covalently linked to an MRI agent and an optical dye
BR9815240A (pt) * 1997-10-09 2001-10-30 Perio Prod Ltd Sistema de fornecimento de medicamentogastrointestinal de liberação total retardada
WO1999020316A1 (en) * 1997-10-20 1999-04-29 Board Of Regents, The University Of Texas System Single photon-emitting radiotraces and methods for their use
JP2002512942A (ja) * 1998-04-28 2002-05-08 ヤーゴウテック アーゲー ヒアルロナン系像形成剤
DE69938612T2 (de) * 1998-11-10 2009-07-09 Netech Inc., Kawasaki Funktionelle chitosanderivate
US6692724B1 (en) 1999-10-25 2004-02-17 Board Of Regents, The University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US7067111B1 (en) 1999-10-25 2006-06-27 Board Of Regents, University Of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US6399951B1 (en) 2000-02-02 2002-06-04 Ut-Battelle, Llc Simultaneous CT and SPECT tomography using CZT detectors
AU2001254550A1 (en) 2000-04-20 2001-11-07 The University Of British Columbia Radiometal complexes of 2-pyrrolylthiones for imaging a therapy
HUP0400758A3 (en) 2000-11-03 2005-02-28 Bristol Myers Squibb Pharma Co Simultaneous dual isotope imaging of cardiac perfusion and cardiac inflammation
US6623721B2 (en) 2000-12-18 2003-09-23 Draximage, Inc. Bifunctional chelating compounds containing hydroxamic acid residues
CA2444483A1 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
GB0111204D0 (en) 2001-05-08 2001-06-27 Mertek Ltd High flux,high energy photon source
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
CA2476589C (en) 2002-02-27 2014-02-25 Pharmain, Ltd. Compositions for delivery of therapeutics and other materials, and methods of making and using the same
US7001888B2 (en) * 2002-03-29 2006-02-21 Threshold Pharmaceuticals, Inc. Compositions and methods for treating cancer
JP2005531647A (ja) * 2002-04-11 2005-10-20 カルボマー インク 新規なイメージングプローブ
US20040022729A1 (en) * 2002-07-31 2004-02-05 Uzgiris Egidijus E. Method for binding molecular agents to angiogencic blood vessels
US20040042959A1 (en) 2002-08-28 2004-03-04 Michael Montalto Imaging cell death in vivo using non-radionuclide contrast agents
US7303741B2 (en) 2002-09-23 2007-12-04 General Electric Company Systems and methods for high-resolution in vivo imaging of biochemical activity in a living organism
EP2316493A3 (en) 2002-11-07 2011-08-10 Board of Regents, The University of Texas System Ethylenedicysteine (EC)-drug conjugates, compositions and methods for tissue specific disease imaging
US20050024380A1 (en) 2003-07-28 2005-02-03 Lin Lin Method for reducing random access memory of IC in display devices
US7790141B2 (en) * 2003-08-11 2010-09-07 Pathak Holdings, Llc Radio-opaque compounds, compositions containing same and methods of their synthesis and use
US9050378B2 (en) 2003-12-10 2015-06-09 Board Of Regents, The University Of Texas System N2S2 chelate-targeting ligand conjugates
CN1969190A (zh) * 2004-04-20 2007-05-23 爱默蕾大学 多峰性纳米结构,其制造方法以及其使用方法

Also Published As

Publication number Publication date
AU2011200132A1 (en) 2011-02-03
CA2593256A1 (en) 2006-07-13
WO2006074272A2 (en) 2006-07-13
AU2011200132B2 (en) 2012-10-11
WO2006074272A3 (en) 2007-05-31
KR20070106711A (ko) 2007-11-05
WO2006074272A8 (en) 2006-12-28
AU2006204045B2 (en) 2010-10-14
US8147805B2 (en) 2012-04-03
US20120276005A1 (en) 2012-11-01
JP2008531755A (ja) 2008-08-14
EP1846042A2 (en) 2007-10-24
US20060182687A1 (en) 2006-08-17
CN101137398B (zh) 2012-07-04
CN101137398A (zh) 2008-03-05
AU2006204045A1 (en) 2006-07-13
KR101313712B1 (ko) 2013-10-01
IL184415A0 (en) 2008-12-29
BRPI0606395A2 (pt) 2009-06-23

Similar Documents

Publication Publication Date Title
WO2006074272A8 (en) Conjugates for dual imaging and radiochemotherapy: composition, manufacturing, and applications
WO2008045604A3 (en) Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
PH12023550266A1 (en) Anti-ceacam5 antibodies and conjugates and uses thereof
AU2006226733A8 (en) Antibodies against CD38 for treatment of multiple myeloma
MX2010005022A (es) Anticuerpos que unen celulas dendriticas y epiteliales 205 (dec-205) humanas.
WO2007073499A3 (en) Epha2 bite molecules and uses thereof
DE60323756D1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
TW200716606A (en) Chemical compounds
TW200800963A (en) Chemical compounds
PL1853602T3 (pl) Związki chemiczne
PL1853588T3 (pl) Związki chemiczne
WO2009083009A3 (en) Monoclonal antibodies against cd32b
TW200700093A (en) Pharmaceutical composition for the treatment of cancer
WO2005103081A3 (en) Human monoclonal antibodies against cd20
UA92505C2 (ru) Композиции на основе антитела против cd3
IL176007A0 (en) Antibodies specific to c35 and pharmaceutical compositions containing the same
BR112021025720A2 (pt) Conjugados anticorpo-fármaco de fator antitecido e métodos relacionados
WO2011028334A3 (en) Synthesis and isolation of dendrimer systems
CY1111256T1 (el) Παραγωγα αζαδικυκλοοκταν-3-ονης και χρηση τους
UA99602C2 (ru) Антитело, специфически связывающееся с jam-a, способное ингибировать пролиферацию опухолевых клеток
NO20084821L (no) Formuleringer og metoder for celleimaging og terapi
WO2011112566A3 (en) Basigin binding proteins
EA201100565A1 (ru) Композиции и способы лечения заболеваний кишечника с использованием гранулированного мезаламина
WO2009013358A3 (en) Polysaccharides grafted by polyamines for the preparation of radiopharmaceutical compositions
WO2007075921A3 (en) De-n-acetyl sialic acid antigens, antibodies thereto, and methods of use in cancer therapy

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application